The estimated Net Worth of James D Arecca is at least $386 Tausend dollars as of 10 August 2021. Mr. Arecca owns over 217,167 units of TherapeuticsMD stock worth over $386,101 and over the last 9 years he sold TXMD stock worth over $0. In addition, he makes $0 as Chief Financial Officer at TherapeuticsMD.
James has made over 1 trades of the TherapeuticsMD stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 217,167 units of TXMD stock worth $386,101 on 10 August 2021.
The largest trade he's ever made was exercising 217,167 units of TherapeuticsMD stock on 10 August 2021 worth over $386,101. On average, James trades about 7,239 units every 0 days since 2016. As of 10 August 2021 he still owns at least 217,167 units of TherapeuticsMD stock.
You can see the complete history of Mr. Arecca stock trades at the bottom of the page.
James C. D'Arecca serves as Chief Financial Officer of the Company. He served as Senior Vice President and Chief Accounting Officer of Allergan plc (formerly known as Actavis plc) from August 2013 until its merger with AbbVie Inc. in May 2020. Mr. D’Arecca was a key member of the finance team through Allergan’s journey from a generics manufacturer (Watson/Actavis) to a leading global pharmaceutical company. Mr. D’Arecca joined Actavis from Bausch & Lomb, where he served as its Chief Accounting Officer. Prior to Bausch & Lomb, Mr. D’Arecca served in various roles of increasing responsibility at Merck & Co. Inc. and Schering-Plough in finance and business development. He also spent 13 years with PricewaterhouseCoopers, with an industry focus on pharmaceuticals, medical devices, and consumer products. Mr. D’Arecca holds an M.B.A. from Columbia University and a B.S. in accounting from Rutgers University. He is a Certified Public Accountant.
James Arecca is 49, he's been the Chief Financial Officer of TherapeuticsMD since 2020. There are 18 older and 6 younger executives at TherapeuticsMD. The oldest executive at TherapeuticsMD, Inc. is Tommy Thompson, 78, who is the Independent Chairman of the Board.
Over the last 13 years, insiders at TherapeuticsMD have traded over $60,334,483 worth of TherapeuticsMD stock and bought 3,746,989 units worth $33,644,571 . The most active insiders traders include Cooper C. Collins, Brian Bernick und Robert G Finizio. On average, TherapeuticsMD executives and independent directors trade stock every 30 days with the average trade being worth of $233,918. The most recent stock trade was executed by Cooper C. Collins on 22 August 2024, trading 4,094 units of TXMD stock currently worth $7,083.
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
TherapeuticsMD executives and other stock owners filed with the SEC include: